Stockreport

Generex Biotechnology Publishes Response to Congressional Letter Calling for COVID-19 Challenge Studies and Alternative Solution to Accelerate Vaccine Development

GENEREX BIOTECHNOLOGY  (GNBT) 
US:NASDAQ Investor Relations: generex.com/investor
PDF Generex strategy offers ethical and safe solution to rapid vaccine development with Ii-Key-SARS-CoV-2 peptide vaccineSARS-CoV-2 mechanism of infection still largely unkn [Read more]